Moderna Projects Lower Revenue in 2025 Due to Flagging COVID-19 Vaccine Sales

Revenue in the third quarter was down 45 percent from the third quarter of the prior year.
Moderna Projects Lower Revenue in 2025 Due to Flagging COVID-19 Vaccine Sales
Moderna COVID-19 vaccine, in this file illustration image. Joe Raedle/Getty Images
Zachary Stieber
Zachary Stieber
Senior Reporter
|Updated:
0:00

Moderna on Nov. 6 revised its revenue projections for 2025 after third-quarter sales plummeted from a year prior.

Moderna made just $1 billion in the third quarter, down 45 percent from the $1.9 billion it made in the third quarter of 2024.

Zachary Stieber
Zachary Stieber
Senior Reporter
Zachary Stieber is a senior reporter for The Epoch Times based in Maryland. He covers U.S. and world news. Contact Zachary at [email protected]
twitter
truth